A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR)
This study tests a new oral medicine called VVD-133214, either alone or with other cancer therapies, for people with advanced solid tumors. Researchers want to see how safe the drug is and how well it blocks the growth of certain types of cancer.
You might be able to join if you have an advanced solid tumor with specific genetic features known as MSI-high or dMMR, and can perform your daily activities. Depending on the treatment group, you may need to have tried certain prior treatments or be newly diagnosed.
You will take the study drug as a pill, and depending on your group, you may also receive other approved cancer drugs like pembrolizumab or bevacizumab. Your health and any side effects will be closely monitored by the medical team throughout the study.
This study is currently recruiting participants at locations in Arizona and California, United States.
- 1Testing a new cancer pill called VVD-133214
- 2For adults with advanced solid tumors having specific genetic markers
- 3Currently recruiting patients at select medical centers
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.